Covid-19 and infectious disease initiative

There has been unprecedented activity to develop a COVID-19 vaccine. The first vaccine candidate was created 42 days after the genetic sequencing of the novel coronavirus.

If we speak of the hurdles in bringing this vaccine in use, validating unproven platform technologies, safety and protection of vaccine candidates against Covid-19 and delivering high impact vaccine profile are at the top. At the same time from a regulatory standpoint, the guidelines are still being finalised for granting emergency use authorisations.

While asymptomatic in some, SARS-CoV-2 infection can cause viral pneumonia that progresses to acute respiratory distress syndrome (ARDS), and even multi-organ failure, in severe cases. However, it remains unclear whether disease severity is caused by the viral infection, the host response, or both. Our teams are involved in understanding the immune perturbations induced by SARS-CoV-2. The immunological signatures of severe COVID-19 is at an evolving stage at its best.

Development of therapeutic strategies to treat SARS-CoV-2 infection remains a worldwide challenge, mainly attributed to the complexity of the clinical manifestations and an overall lack of understanding of severe COVID-19 immunopathogenesis. Small patient number studies, analysis on the available immune phenotypes have given us information of great significance however so far the world has fallen short of providing a definitive prevention or a therapeutic resolve to this pandemic.

Koru has risen to this challenge and our scientists are working relentlessly to contribute towards this challenge. We at Koru believe one world one team. Let us fight together, for a better tomorrow.

Our research efforts are directed towards drug repurposing by investigating known drug compounds for new disease applications. We are moving aggressively to expand our investigation in order to establish several lead compounds in the foreseeable future.